All Drug Discovery Processes articles – Page 34
-
NewsNew collaboration targets key challenges in fibrosis treatment
Deep Science Ventures and General Inception are teaming up to tackle fibrosis. Together, they aim to create a company focused on developing new treatments for fibrotic diseases.
-
NewsInjectable gel targets osteoarthritis pain
Hydrocelin shows promising preclinical results in treating osteoarthritis, offering pain relief and potential joint protection with no observed side effects.
-
NewsTessera's gene editing offers hope for sickle cell patients
Find out how Tessera's latest advancements in gene editing bring promising solutions to treat sickle cell disease.
-
NewsCancer Research Horizons collaborates with Diamond to accelerate drug discovery
Cancer Research Horizons has teamed up with Diamond Light Source to drive the discovery of new cancer treatments.
-
ArticleIn vivo CAR T: Faster, cheaper, and more effective cancer care
Find out how in vivo cell therapies could transform cancer treatment by providing faster, more affordable, and accessible options for more patients.
-
ArticleOncology advances through the lens of women in STEM
Dr Pooja Hingorani opens up about her journey in oncology research, the obstacles she’s overcome as a woman in STEM, and her mission to transform cancer care.
-
NewsNKTR-255 shows positive results in lymphoma therapy
Nektar Therapeutics' NKTR-255 improves CAR-T therapy outcomes in lymphoma patients. Find out how this development could impact cancer treatment.
-
ArticleNew targeted therapies show promise in lung cancer treatment
Recent advancements in targeted therapies and immunotherapies are transforming lung cancer treatment. Discover how these innovations are improving outcomes and providing hope for patients.
-
NewsRefeyn launches software platform to automate mass photometry workflows
Refeyn's new software automates mass photometry workflows, delivering faster and more consistent results for bioanalytical applications.
-
NewsNovartis licenses innovative treatment for Huntington’s disease
Novartis has teamed up with PTC Therapeutics to develop PTC518, a groundbreaking treatment that targets the cause of Huntington's disease, offering new hope for patients.
-
ArticleToxicology transformed: Why accuracy now leads the way
Regulatory changes are reshaping toxicology, with precision now at the forefront. We explore how accurate target analysis is transforming drug development, particularly for biotherapeutics.
-
NewsSmall molecule drug discovery market projected to hit $106 billion by 2031
The global small molecule drug discovery market is set for significant growth. Explore the key factors driving this expansion, from rising R&D investments to the increasing role of AI and CROs.
-
ArticleAI paves the way for new immunotherapy targets
To fully unlock the potential of immunotherapy for cancer patients, we need better targets, not just better treatments. Hear from Michelle Teng, CEO of Etcembly, on how AI is decoding the immune repertoire and designing new therapies.
-
NewsKey enzyme discovery marks a step forward in Alzheimer’s treatment
Scientists have decoded the 3D structure of a key enzyme linked to Alzheimer's disease. This breakthrough opens up new possibilities for targeted drug development and better treatment options.
-
ArticleNobel Prize celebrates AI's role in protein structure innovation
The 2024 Nobel Prize in Chemistry honours AI's transformative impact on protein science, with breakthroughs set to reshape drug development.
-
NewsE. coli alters ribosomes to survive antibiotic treatment
New study shows E. coli resists antibiotics by modifying its ribosome structure, blocking drug binding and enabling growth despite treatment.
-
ArticleScientific workflow for hypothesis testing in drug discovery: Part 1 of 3
Explore the step-by-step scientific workflow behind drug discovery, from formulating hypotheses to analysing data, ensuring accurate and reliable results.
-
ArticleNew insights into the role of viral capsids in gene therapy safety
Viral capsid assembly and quality are key factors in gene therapy success and safety. Here, Dr Chelsea Pratt explores how cutting-edge tools are enabling scientists to tackle these challenges and improve patient outcomes.
-
NewsNew CAR-T therapy shows promise in leukaemia treatment
Obecabtagene autoleucel (obe-cel) has demonstrated strong efficacy in treating relapsed B-cell leukemia, with high response rates and minimal side effects.
-
NewsMetrion Biosciences appoints Lee Patterson as CEO
Metrion Biosciences is set to accelerate its global expansion and enhance its leadership in ion channel drug discovery services.